Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy
The tumor immune contexture plays a major role for the clinical outcome of patients. High densities of CD45RO+ T helper 1 cells and CD8+ T cells are associated with improved survival of patients with various cancer entities. In contrast, a higher frequency of tumor-infiltrating M2 macrophages is cor...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fimmu.2020.00364/full |
id |
doaj-1bfe7fe5c6024be1963558088d27f31e |
---|---|
record_format |
Article |
spelling |
doaj-1bfe7fe5c6024be1963558088d27f31e2020-11-25T02:29:35ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-03-011110.3389/fimmu.2020.00364519518Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor TherapyIoana Plesca0Antje Tunger1Antje Tunger2Luise Müller3Rebekka Wehner4Rebekka Wehner5Rebekka Wehner6Xixi Lai7Marc-Oliver Grimm8Sergio Rutella9Michael Bachmann10Michael Bachmann11Michael Bachmann12Marc Schmitz13Marc Schmitz14Marc Schmitz15Faculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyFaculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyFaculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyFaculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, GermanyFaculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyDepartment of Urology, Jena University Hospital, Jena, GermanyJohn van Geest Cancer Research Center, College of Science and Technology, Nottingham Trent University, Nottingham, United KingdomNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, GermanyDepartment of Radioimmunology, Institute of Radiopharmaceutical Cancer Research, Helmholtz Center Dresden-Rossendorf, Dresden, GermanyFaculty of Medicine Carl Gustav Carus, Institute of Immunology, TU Dresden, Dresden, GermanyNational Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, GermanyGerman Cancer Consortium (DKTK), Partner Site Dresden, German Cancer Research Center (DKFZ), Heidelberg, GermanyThe tumor immune contexture plays a major role for the clinical outcome of patients. High densities of CD45RO+ T helper 1 cells and CD8+ T cells are associated with improved survival of patients with various cancer entities. In contrast, a higher frequency of tumor-infiltrating M2 macrophages is correlated with poor prognosis. Recent studies provide evidence that the tumor immune architecture also essentially contributes to the clinical efficacy of immune checkpoint inhibitor (CPI) therapy in patients. Pretreatment melanoma samples from patients who experienced a clinical response to anti-programmed cell death protein 1 (PD-1) treatment show higher densities of infiltrating CD8+ T cells compared to samples from patients that progressed during therapy. Anti-PD-1 therapy results in an increased density of tumor-infiltrating T lymphocytes in treatment responders. In addition, elevated frequencies of melanoma-infiltrating TCF7+CD8+ T cells are correlated with beneficial clinical outcome of anti-PD-1-treated patients. In contrast, a high density of tumor-infiltrating, dysfunctional PD-1+CD38hi CD8+ cells in melanoma patients is associated with anti-PD-1 resistance. Such findings indicate that comprehensive tumor immune contexture profiling prior to and during CPI therapy may lead to the identification of underlying mechanisms for treatment response or resistance, and the design of improved immunotherapeutic strategies. Here, we focus on studies exploring the impact of intratumoral T and B cells at baseline on the clinical outcome of CPI-treated cancer patients. In addition, recent findings demonstrating the influence of CPIs on tumor-infiltrating lymphocytes are summarized.https://www.frontiersin.org/article/10.3389/fimmu.2020.00364/fullcancer immunotherapyimmune architectureimmune monitoringimmune checkpoint inhibitioncytotoxic T lymphocyte antigen 4programmed cell death protein 1 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Ioana Plesca Antje Tunger Antje Tunger Luise Müller Rebekka Wehner Rebekka Wehner Rebekka Wehner Xixi Lai Marc-Oliver Grimm Sergio Rutella Michael Bachmann Michael Bachmann Michael Bachmann Marc Schmitz Marc Schmitz Marc Schmitz |
spellingShingle |
Ioana Plesca Antje Tunger Antje Tunger Luise Müller Rebekka Wehner Rebekka Wehner Rebekka Wehner Xixi Lai Marc-Oliver Grimm Sergio Rutella Michael Bachmann Michael Bachmann Michael Bachmann Marc Schmitz Marc Schmitz Marc Schmitz Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy Frontiers in Immunology cancer immunotherapy immune architecture immune monitoring immune checkpoint inhibition cytotoxic T lymphocyte antigen 4 programmed cell death protein 1 |
author_facet |
Ioana Plesca Antje Tunger Antje Tunger Luise Müller Rebekka Wehner Rebekka Wehner Rebekka Wehner Xixi Lai Marc-Oliver Grimm Sergio Rutella Michael Bachmann Michael Bachmann Michael Bachmann Marc Schmitz Marc Schmitz Marc Schmitz |
author_sort |
Ioana Plesca |
title |
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
title_short |
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
title_full |
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
title_fullStr |
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
title_full_unstemmed |
Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy |
title_sort |
characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Immunology |
issn |
1664-3224 |
publishDate |
2020-03-01 |
description |
The tumor immune contexture plays a major role for the clinical outcome of patients. High densities of CD45RO+ T helper 1 cells and CD8+ T cells are associated with improved survival of patients with various cancer entities. In contrast, a higher frequency of tumor-infiltrating M2 macrophages is correlated with poor prognosis. Recent studies provide evidence that the tumor immune architecture also essentially contributes to the clinical efficacy of immune checkpoint inhibitor (CPI) therapy in patients. Pretreatment melanoma samples from patients who experienced a clinical response to anti-programmed cell death protein 1 (PD-1) treatment show higher densities of infiltrating CD8+ T cells compared to samples from patients that progressed during therapy. Anti-PD-1 therapy results in an increased density of tumor-infiltrating T lymphocytes in treatment responders. In addition, elevated frequencies of melanoma-infiltrating TCF7+CD8+ T cells are correlated with beneficial clinical outcome of anti-PD-1-treated patients. In contrast, a high density of tumor-infiltrating, dysfunctional PD-1+CD38hi CD8+ cells in melanoma patients is associated with anti-PD-1 resistance. Such findings indicate that comprehensive tumor immune contexture profiling prior to and during CPI therapy may lead to the identification of underlying mechanisms for treatment response or resistance, and the design of improved immunotherapeutic strategies. Here, we focus on studies exploring the impact of intratumoral T and B cells at baseline on the clinical outcome of CPI-treated cancer patients. In addition, recent findings demonstrating the influence of CPIs on tumor-infiltrating lymphocytes are summarized. |
topic |
cancer immunotherapy immune architecture immune monitoring immune checkpoint inhibition cytotoxic T lymphocyte antigen 4 programmed cell death protein 1 |
url |
https://www.frontiersin.org/article/10.3389/fimmu.2020.00364/full |
work_keys_str_mv |
AT ioanaplesca characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT antjetunger characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT antjetunger characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT luisemuller characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT rebekkawehner characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT rebekkawehner characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT rebekkawehner characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT xixilai characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT marcolivergrimm characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT sergiorutella characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT michaelbachmann characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT michaelbachmann characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT michaelbachmann characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT marcschmitz characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT marcschmitz characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy AT marcschmitz characteristicsoftumorinfiltratinglymphocytespriortoandduringimmunecheckpointinhibitortherapy |
_version_ |
1724832260610326528 |